Enzymes and Alzheimer's Disease: Pioneering Drug Development Strategies

Abstract: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and functional impairment. Despite extensive research, effective treatments remain elusive, highlighting the need for innovative therapeutic approaches. This review article explores enzymatic targets and drug development strategies aimed at combating AD. Key enzymatic targets include beta-secretase (BACE1), gamma-secretase, and tau protein kinases, all of which play critical roles in the pathogenesis of AD. BACE1 and gamma-secretase are involved in the production of amyloid-beta (Aβ) peptides, whose aggregation forms the hallmark amyloid plaques in AD brains. Inhibitors targeting these enzymes aim to reduce Aβ production and accumulation. Tau protein kinases, such as glycogen synthase kinase-3 (GSK-3) and cyclin-dependent kinase 5 (CDK5), are implicated in tau hyperphosphorylation and subsequent neurofibrillary tangle formation. Modulating these kinases offers the potential for reducing tau pathology. The review further discusses various drug development strategies, including small-molecule inhibitors, monoclonal antibodies, and gene therapy. Small molecule inhibitors, such as BACE1 and gamma-secretase inhibitors, have shown promise in preclinical studies but face challenges related to specificity and side effects. Monoclonal antibodies targeting Aβ and tau provide an alternative approach, with several candidates currently undergoing clinical trials. Gene therapy represents a cutting-edge strategy aiming to correct or modulate disease-causing genetic mutations. In summary, targeting enzymatic pathways involved in AD pathogenesis offers a promising avenue for drug development. While significant challenges remain, ongoing research and clinical trials continue to advance our understanding and potential treatment options for this debilitating disease.